Clinical trial
A Multi-Center, Randomized, Double-Blind Placebo Controlled Multiple-Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis, Followed by an Open-Label Extended Dosing Period
NCT05633459 is registered in ClinicalTrials.gov with QurAlis Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Randomized, Double-Blind Placebo Controlled Multiple-Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis, Followed by an Open-Label Extended Dosing Period
- Lead sponsor
- QurAlis Corporation
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- December 16, 2022
- Completion date
- November 30, 2027
- Enrollment
- 69 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.